abicipar pegol

DRUG8 trials

Sponsors

Allergan

Conditions

Macular DegenerationMacular Edema

Phase 1

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD

CompletedNCT02859766

AllerganMacular Degeneration

Start: 2016-12-07End: 2017-10-20Updated: 2018-02-08

Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD

CompletedNCT03335852

AllerganMacular Degeneration

Start: 2017-11-28End: 2018-10-08Updated: 2018-11-01

Phase 2

A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration

CompletedNCT02181504

AllerganMacular Degeneration

Start: 2014-09-30End: 2015-12-31Updated: 2017-04-25

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

CompletedNCT02181517

AllerganMacular Degeneration

Start: 2014-07-31End: 2015-03-31Updated: 2016-05-17

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

CompletedNCT02186119

AllerganMacular Edema

Start: 2014-07-31End: 2015-06-30Updated: 2015-07-14

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

CompletedNCT03539549

AllerganMacular Degeneration

Start: 2018-05-25End: 2019-02-27Updated: 2020-08-03

Phase 3

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

CompletedNCT02462928

AllerganMacular Degeneration

Start: 2015-06-25End: 2019-06-19Updated: 2020-07-28

Safety and Efficacy of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

CompletedNCT02462486

AllerganMacular Degeneration

Start: 2015-06-25End: 2019-06-06Updated: 2020-07-30